发明名称 |
NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY |
摘要 |
The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride. |
申请公布号 |
US2016000733(A1) |
申请公布日期 |
2016.01.07 |
申请号 |
US201514666077 |
申请日期 |
2015.03.23 |
申请人 |
Weg Stuart L. |
发明人 |
Mermelstein Fred H.;Albin Randi |
分类号 |
A61K31/135;A61K9/00;A61K31/14 |
主分类号 |
A61K31/135 |
代理机构 |
|
代理人 |
|
主权项 |
1. A spray device for intranasal delivery of a pharmaceutical composition, wherein the spray device comprises a pharmaceutical composition comprising an aqueous solution containing about 10% ketamine hydrochloride and about 0.001% to about 0.2% benzalkonium chloride, wherein the composition does not cause any significant neurotoxicity, and wherein the level of neurotoxicity is comparable to sterile water when administered. |
地址 |
Franklin Lakes NJ US |